These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2803179)

  • 1. Spontaneous activation of reconstituted and serum C1 and the role of C1-inhibitor.
    Schumaker VN; Tseng Y; Poon PH; Bianchino AC; Zavodszky P
    Behring Inst Mitt; 1989 Jul; (84):102-10. PubMed ID: 2803179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor.
    Bianchino AC; Poon PH; Schumaker VN
    J Immunol; 1988 Dec; 141(11):3930-6. PubMed ID: 3183385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous activation of serum C1 in vitro. Role of C1 inhibitor.
    Tseng Y; Poon PH; Zavodszky P; Schumaker VN
    J Immunol; 1991 Sep; 147(6):1884-90. PubMed ID: 1890306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism.
    Ziccardi RJ
    J Immunol; 1982 Jun; 128(6):2500-4. PubMed ID: 6281332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-independent activation of C1, the first component of complement, by cardiolipin.
    Kovacsovics T; Tschopp J; Kress A; Isliker H
    J Immunol; 1985 Oct; 135(4):2695-700. PubMed ID: 4031497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified low density lipoproteins differentially bind and activate the C1 complex of complement.
    Biró A; Thielens NM; Cervenák L; Prohászka Z; Füst G; Arlaud GJ
    Mol Immunol; 2007 Feb; 44(6):1169-77. PubMed ID: 16938346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of human C1: analysis with Western blotting reveals slow self-activation.
    Hosoi S; Circolo A; Borsos T
    J Immunol; 1987 Sep; 139(5):1602-8. PubMed ID: 3624867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of plicatic acid on human serum complement includes interference with C1 inhibitor function.
    Giclas PC
    J Immunol; 1982 Jul; 129(1):168-72. PubMed ID: 6979566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood.
    Salvesen B; Nielsen EW; Harboe M; Saugstad OD; Mollnes TE
    Mol Immunol; 2009 Feb; 46(4):688-94. PubMed ID: 18950866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
    Füst G; Czink E; Minh D; Miszlay Z; Varga L; Hollán SR
    Clin Exp Immunol; 1985 Jun; 60(3):489-95. PubMed ID: 4017286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role for the third constant domain of the IgG H chain in activation of complement in the presence of C1 inhibitor.
    Okada M; Utsumi S
    J Immunol; 1989 Jan; 142(1):195-201. PubMed ID: 2491872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1.
    Tenner AJ; Frank MM
    J Immunol; 1986 Jul; 137(2):625-30. PubMed ID: 3722818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of C1 activation by a monoclonal anti-C1q antibody and its (Fab)2 fragments.
    Kilchherr E; Schumaker VN; Bianchino AC; Curtiss LK
    J Immunol; 1987 Feb; 138(3):849-55. PubMed ID: 3492535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1).
    Windfuhr JP; Alsenz J; Loos M
    Mol Immunol; 2005 Apr; 42(6):657-63. PubMed ID: 15781109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between the binding ability and the rate of activation of the complement component C1.
    Folkerd EJ; Gardner B; Hughes-Jones NC
    Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.